XIENCE™ Family of Drug-Eluting Stents

The World's Leading Drug-Eluting Stents (DES), with Unparalleled Clinical Outcomes¹

XIENCE™ Family of Drug-Eluting Stents

Anti-Thrombotic Fluoropolymer Promotes Safety

The XIENCE™ Stent polymer with a fluorinated surface has shown protective attributes—the ability to tightly bind albumin to create a “protective cloak” around the stent.2
 

The XIENCE™ Stent Fluoropolymer—Proven to Protect2,3

Another factor that sets XIENCE™ Stent apart is its fluoropolymer coating. Unlike other polymer coatings, the fluoropolymer interacts with proteins in the blood in a way that reduces thrombus formation—a process known as fluoropassivation.
 

Fluoropassivation Leads to Thromboresistance3

XIENCE™ Stent, widely considered to be the gold standard for patient safety and efficacy, is coated with a fluoropolymer.


THE XIENCE™ STENT FLUOROPOLYMER: PROVEN TO PROTECT

Due to thromboresistance and low inflammatory responses, fluorinated surfaces encourage faster endothelization and healing.4

Three step graph showing how the albumin, which the XIENCE Stent’s fluoropolymer retains, minimizes inflammatory response, promotes endothelial growth and leads to positive outcomes.

Fluoropolymer Stent vs Bare Metal Stent and Biodegradable Polymer Stent

Moreover, the XIENCE™ Stent fluoropolymer has minimal coating defects compared to biodegradable polymer DES (BP-DES).9

In contrast to the visual above, most stents available today—biodegradable polymer stents, durable polymer stents or bare metal stents—have non-fluorinated surfaces that interact with proteins in the following ways:

  • The surfaces attract less albumin and more fibrinogen.10
  • The fibrinogen, in turn, leads to more platelet adhesion and activation.11
  • The platelets, fibrinogen and red blood cells can aggregate and create a thrombus.12

XIENCE™ Stent Fluoropolymer vs Other Types of Stents

XIENCE™ Stent’s fluoropolymer demonstrates the fewest platelets adhering to the stent surface—an important factor in stent thrombosis.3 This fluoropolymer can protect patients from both acute and long-term complications.3,13

Representative confocal photomicrographs stained for platelets (CD42b/CD61). N=5 per stent. This preclinical ex vivo porcine shunt model used aspirin-only antiplatelet therapy.

XIENCE Stent shows significantly less platelet adhesion vs other stents: Synergy, Orsiro, Ultimaster, Resolute Onyx, Biofreedom.
XIENCE™ Stent: Least Blood Platelet Adhesion (p < 0.01)
When Using Aspirin Monotherapy3
XIENCE Stent comparison


XIENCE™ Stent: Least Blood Platelet Adhesion (p < 0.05) When Using P2Y12 Inhibitor Monotherapy3

Representative confocal photomicrographs stained for platelets (CD42b/CD61). N=8 per stent. This preclinical ex vivo porcine shunt model used clopidogrel-only antiplatelet therapy.

XIENCE Stent comparison


XIENCE™ Stent: Least Blood Platelet Adhesion (p < 0.05) When Using P2Y12 Inhibitor Monotherapy3

Representative confocal photomicrographs stained for platelets (CD42b/CD61). N=8 per stent. This preclinical ex vivo porcine shunt model used clopidogrel-only antiplatelet therapy.

XIENCE™ Stent: Least Blood Platelet Adhesion When Using Heparin Only14

Expert's Point of View: Reduced Inflammatory Response

In the images “on the right you can see the [pro-thrombotic] platelet adherence. XIENCE™ Stent [the image at the bottom] has hardly any attachments to it.” — Renu Virmani, MD, referring to the photomicrographs, where green indicates platelet adhesion.
 

NOTE: Full video presented at TCTMD 2016. Abbott Sponsored Event.
Visual Evidence of Fluoropolymer Safety

Visual Evidence of Fluoropolymer Safety

In several analyses, XIENCE™ Stent exhibits the most thromboresistance when compared to several different BP-DES.3,14

Least Thrombus Area with XIENCE™ Stent vs BP-DES14

Ex vivo porcine photomicrographs reveal the least thrombus area on XIENCE™ Stent (green areas are platelets).

Real-Time Platelet-Device Interaction

CVPath Institute also conducted tests to show real-time platelet-device interaction between different types of stents.
 

XIENCE™ Stent
Compared with Synergy
XIENCE™ Stent
Compared with Other DES

This preclinical model used in vitro human blood with heparin only. Representative confocal photomicrographs stained for platelets. Real-time platelet-device interaction was visualized under confocal microscopy and recorded in a time-lapse video. Image processing quantified platelet deposition on devices.

Manuals & Technical Resources

Manuals & Technical Resources

Order Cardiovascular Products

Cardiovascular Products

Customer Service

Customer Service

References

  1. Zanchin C, et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675. Serruys P, et al. N Engl J Med. 2010;363:136-146. Shiomi H, et al. JACC Cardiovasc Interv. 2019;12:637-647. Kufner S, et al. Circulation. 2019:139(3):325-333. Palmerini T, et al. Lancet. 2013;379:1393-1402. Bangalore S, et al. Circulation. 2012;125:2873-2891. Bangalore S, et al. Circ Cardiovasc Interv. 2013;6(6):378-390. Pilgrim T, et al. Lancet. 2014;384:2111-2122. Pilgrim T, et al. Lancet. 2018;392:737-746. Data on file at Abbott.
  2. Garfinkle AM, et al. Trans Am Soc Artif Intern Organs. 1984;30:432-439. Ao PY, et al. Eur J Vasc Endovasc Surg. 2000;20:241-249. Jinnouchi H, et al. EuroIntervention. 2020;EIJ-D-19-00938.
  3. Jinnouchi H, et al. J Am Coll Cardiol. 2019;74:(Suppl B):TCT-291. Sato Y, et al. PCR eCourse 2020.
  4. Szott LM, et al. Biointerphases. 2016;11:029806. Wertz CF, et al. Langmuir. 2001;17:3006-3016. Joner M, et al. J Am Coll Cardiol. 2008 Jul, 52 (5) 333-342.
  5. Panchalingam V, et al. ASAIO J. 1993;39:M305-M309.
  6. Paton DM, et al. U.S. Patent 5,356,668. Garfinkle AM, et al. Trans Am Soc Artif Intern Organs. 1984;30:43-439.
  7. Szott LM, et al. Biointerphases. 2016;11:029806.
  8. Mehran R, et al. TCT Connect 2020, XIENCE 28/90.
  9. Data on file at Abbott.
  10. Panchalingam V, et al. ASAIO J. 1993;39:M305-M309. Jinnouchi H, et al. EuroIntervention. 2020;EIJ-D-19-00938.
  11. Wu Y, et al. J Biomed Mater Res. 2005;74(4):722-738. Tsai WB, et al. J Biomed Mater Res. 1999:44:130-139.
  12. Garfinkle AM, et al. Trans Am Soc Artif Intern Organs. 1984;30:432-439.
  13. Kamberi M, et al. J Biomed Mater Res B Appl Biomater. 2018;106(5):1721-1729. Zanchin, C. et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675. Serruys P, et al. N Engl J Med. 2010;363:136-146. Shiomi H, et al. JACC Cardiovasc Interv. 2019;12(7):637-647. Kufner S, et al. Circulation. 2019:139(3):325-333.
  14. Otsuka F, et al. JACC Cardiovasc Interv. 2015;8:1248-1260.

MAT-2408190 v1.0

Important Safety Information
 

XIENCE Skypoint™, XIENCE Sierra™, XIENCE Alpine™ (XIENCE™ Family) Everolimus Eluting Coronary Stent Systems

rx-only-logo

Indications

Applies to XIENCE Skypoint™ Stent Systems:

  • Indicated for improving coronary artery luminal diameter in patients, including those with diabetes mellitus, with symptomatic heart disease due to de novo native coronary artery lesions ≤ 44 mm in length with reference vessel diameters of ≥ 2.25 mm to ≤ 5.25 mm and for high bleeding risk patients with coronary arteries lesions ≤ 32 mm in length with a reference vessel diameter of ≥ 2.25 mm and ≤ 5.25 mm.
  • Treating de novo chronic total coronary occlusions.

Applies to XIENCE Sierra™ and XIENCE Alpine™ Stent Systems:

  • Indicated for improving coronary artery luminal diameter in patients, including those at high risk for bleeding and those with diabetes mellitus, with symptomatic heart disease due to de novo native coronary artery lesions (length ≤ 32 mm) with reference vessel diameters of ≥ 2.25 mm to ≤ 4.25 mm.
  • Treating de novo chronic total coronary occlusions.
     

Contraindications

The XIENCE Skypoint™, XIENCE Sierra™ and XIENCE Alpine™ Stent Systems are contraindicated for use in:

  • Patients who cannot tolerate, including allergy or hypersensitivity to, procedural anticoagulation or the post-procedural antiplatelet regimen.
  • Patients with hypersensitivity or contraindication to everolimus or structurally-related compounds, or known hypersensitivity to stent components (cobalt, chromium, nickel, tungsten, methacrylic polymer, fluoropolymer), or with contrast hypersensitivity.
     

Warnings

  • Each stent and the delivery system are for single use only. Do not reuse, reprocess, or resterilize. Note the product “Use by” date on the package. Reuse, reprocessing, or resterilization may compromise the structural integrity of the device and / or delivery system and / or lead to device failure, which may result in patient injury, illness, or death. Reuse, reprocessing, or resterilization may also create a risk of contamination of the device and / or cause patient infection or cross-infection, including, but not limited to, the transmission of infectious disease(s) from one patient to another. Contamination of the device and / or delivery system may lead to injury, illness, or death of the patient.
  • It is not recommended to treat patients having a lesion that prevents complete inflation of an angioplasty balloon.
  • Antiplatelet therapy should be administered post-procedure.
  • This product should not be used in patients who are not likely to comply with the recommended antiplatelet therapy.
  • Judicious selection of patients is necessary, since the use of this device carries the associated risk of stent thrombosis, vascular complications, and/or bleeding events.
  • The XIENCE Skypoint™, XIENCE Sierra™ and XIENCE Alpine™ Stent Systems are coated with an everolimus and polymer coating at the full implant stent length. The distal and intermediate portions of the device, the tip, and tapers of the balloon are coated with HYDROCOAT™ Hydrophilic Coating.

Failure to abide by the warnings in this labeling might result in damage to the device coating, which may necessitate intervention or result in serious adverse events.
 

Precautions

  • Implantation of the stent should be performed only by the physicians who have received appropriate training.
  • Stent placement should be performed at centers where emergency coronary artery bypass graft surgery (CABG) can be readily performed.
  • When the XIENCE Skypoint™, XIENCE Sierra™ and XIENCE Alpine™ Stent Systems are used outside the specified Indications for Use, patient outcomes may differ from the results observed in the SPIRIT family of clinical trials. Compared to use within the specified indications for use, the use of the XIENCE Skypoint™, XIENCE Sierra™ and XIENCE Alpine™ Stent Systems in patients and lesions outside of the labeled indications, including more tortuous anatomy, may have an increased risk of adverse events, including stent thrombosis, stent embolization, MI, or death.
  • The extent of the patient’s exposure to drug and polymer is directly related to the number of stents implanted. See Instructions for Use for current data on multiple stent implantation.
  • Safety and effectiveness of the XIENCE Skypoint™, XIENCE Sierra™ and XIENCE Alpine™ Stent Systems have not been established for subject populations with the following clinical settings:
    • Patients with prior brachytherapy of the target lesion or the use of brachytherapy for treated site restenosis.
    • Conjunctive use of the XIENCE Skypoint™, XIENCE Sierra™ and XIENCE Alpine™ Stent Systems with either mechanical atherectomy devices or laser angioplasty catheters.
    • Women who are pregnant or lactating, men intending to father children, pediatric.
    • Unresolved vessel thrombus at the lesion site, coronary artery reference vessel diameters < 2.25 mm or > 4.25 mm, for XIENCE Skypoint™ < 2.25 mm or > 5.25 mm, or lesion lengths >44 mm, lesions located in saphenous vein grafts, lesions located in unprotected left main coronary artery, ostial lesions, or lesions located at a bifurcation or previously stented lesions, diffuse disease or poor flow (TIMI < 1) distal to the identified lesions, excessive tortuosity proximal to or within the lesion, recent Acute Myocardial Infarction (AMI) or evidence of thrombus in target vessel, multivessel disease, and in-stent restenosis.
  • Formal drug interaction studies have not been performed with the XIENCE Skypoint™, XIENCE Sierra™ or XIENCE Alpine™ Stent Systems because of limited exposure to everolimus eluted from XIENCE Skypoint™, XIENCE Sierra™ and XIENCE Alpine™ Stent Systems.
    • Everolimus, the active ingredient in the stents, is an immunosuppressive agent. Consideration should be given to patients taking other immunosuppressive agents or who are at risk for immune suppression.
    • Oral everolimus use in renal transplant and advanced renal cell carcinoma patients was associated with increased serum cholesterol and triglyceride levels, which in some cases required treatment.
    • Nonclinical testing has demonstrated that the XIENCE Sierra™ and XIENCE Alpine™ Stent Systems in single and in overlapped configurations up to 71 mm, for XIENCE Skypoint™ 91 mm in length, are MR Conditional. See Instructions for Use for detailed scanning conditions

Potential Adverse Events

Adverse events that may be associated with PCI treatment procedures and the use of a stent in native coronary arteries include, but are not limited to, the following:

  • Allergic reaction or hypersensitivity to latex, contrast agent anesthesia, device materials, and drug reactions to everolimus, anticoagulation, or antiplatelet drugs
  • Vascular access complications which may require transfusion or vessel repair, including: Catheter site reactions, Bleeding, Arteriovenous fistula; pseudoaneurysm, aneurysm, dissection, perforation/rupture, Embolism, Peripheral nerve injury, Peripheral ischemia
  • Coronary artery complications which may require additional intervention, including: Total occlusion or abrupt closure, Arteriovenous fistula, pseudoaneurysm, aneurysm, dissection. Perforation/rupture, Tissue prolapse/plaque shift, Embolism, Coronary or stent thrombosis, Stenosis or restenosis
  • Pericardial complications which may require additional intervention, including: Cardiac tamponade, Pericardial effusion, Pericarditis.
  • Cardiac arrhythmias
  • Cardiac ischemic conditions (including myocardial ischemia, myocardial infarction (including acute), coronary artery spasm, and unstable or stable angina pectoris)
  • Stroke/Cerebrovascular Accident (CVA) and Transient Ischemic Attack (TIA)
  • System organ failures: Cardio-respiratory arrest, Cardiac failure, Cardiopulmonary failure, Renal Insufficiency/failure, Shock
  • Bleeding
  • Blood cell disorders
  • Hypotension and/or hypertension
  • Infection
  • Nausea and vomiting
  • Palpitations
  • Dizziness
  • Syncope
  • Chest Pain
  • Fever
  • Pain
  • Death


The risks described below include the anticipated adverse events relevant for the cardiac population referenced in the contraindications, warnings and precaution sections of the everolimus labels / SmPCs and / or observed at incidences ≥ 10% in clinical trials with oral everolimus for different indications. Please refer to the drug SmPCs and labels for more detailed information and less frequent adverse events.

  • Abdominal pain
  • Anemia
  • Angioedema
  • Arterial Thrombotic Events
  • Bleeding and coagulopathy
  • Constipation
  • Cough
  • Diabetes mellitus
  • Diarrhea
  • Dyspnea
  • Embryo-fetal toxicity
  • Erythema
  • Erythroderma
  • Headache
  • Hepatic artery thrombosis
  • Hepatic disorders
  • Hypersensitivity to everolimus active substance, or to other rapamycin derivates
  • Hypertension
  • Infection (bacterial, fungal, viral or protozoan infections, including infections with opportunistic pathogens). Polyoma virus-associated nephropathy (PVAN), JC virus-associated progressive multiple leukoencephalopathy (PML), fatal infections and sepsis have been reported in patients treated with oral everolimus
  • Kidney arterial and venous thrombosis
  • Laboratory test alterations
  • Lymphoma and skin cancer
  • Male infertility
  • Menstrual irregularities
  • Nausea
  • Nephrotoxicity
  • Non-infectious pneumonitis
  • Oral ulcerations
  • Pain
  • Pancreatitis
  • Pericardial effusion
  • Peripheral edema
  • Pleural effusion
  • Pneumonia
  • Pyrexia
  • Rash
  • Renal Failure
  • Upper respiratory tract infection
  • Urinary tract infection
  • Venous thromboembolism
  • Vomiting
  • Wound healing complications

There may be other potential adverse events that are unforeseen at this time.

MAT-2100879 v7.0